What question did this study set out to answer?

Evaluate the impact of baseline next generation sequencing on survival outcomes in B-ALL patients undergoing CAR-T therapy.

December 8, 2025Blood

Pre-CAR next generation sequencing informs patient outcomes in children and young adults with B-acute lymphoblastic leukemia

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows pre-CAR next generation sequencing predicts survival in B-ALL patients, indicating relevance for CAR-T treatment.

Evaluate the impact of baseline next generation sequencing on survival outcomes in B-ALL patients undergoing CAR-T therapy.
Conducted a retrospective analysis of patients ≤26 years treated with CAR-T at Stanford.
Assessed baseline disease burden using NGS and immunoglobulin heavy chain ratio on patient outcomes.
Utilized univariate and multivariate Cox regression to analyze survival data.
Lower pre-CAR NGS associated with improved overall survival and event-free survival.
In low tumor burden patients, high IgH/TNC ratio correlated with better event-free survival.
Multivariate analysis indicated that baseline NGS measures are significant for overall patient outcomes.

Davis et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis shows pre-CAR next generation sequencing predicts survival in B-ALL patients, indicating relevance for CAR-T treatment.